Bank of England chief says no rift with UK government as Revolut licence delay draws scrutiny

Bank of England chief says no rift with UK government as Revolut licence delay draws scrutiny


Revolut cards is seen in this illustration photo taken in Krakow, Poland on March 29, 2024. 

Jakub Porzycki | Nurphoto | Getty Images

LONDON — Bank of England Governor Andrew Bailey told CNBC there hasn’t been a “falling out” with the U.K. government over delays to fintech giant Revolut’s long-awaited bank license.

Last week, the Financial Times reported that a meeting arranged by British Finance Minister Rachel Reeves with Revolut and the Prudential Regulation Authority (PRA) — an arm of the BOE that oversees banks — was cancelled after an intervention from Bailey.

Authorizing Revolut as a fully licensed bank has become an important issue for the U.K. government, particularly as key figures in the tech industry have challenged tax changes that affect the wealthy.

However, in an interview with CNBC’s Ritika Gupta on Thursday, Bailey denied any suggestion that relations between the BOE and Treasury had soured over delays to Revolut’s bank license approval process.

“There’s been no falling out between [Reeves] and I on this, or indeed on anything,” he said. “Actually, we have very good relations, and I think both the Bank and the Treasury have made that clear.”

Bailey added that while he couldn’t comment too much on Revolut specifically, the Prudential Regulation Authority is working things through with the digital banking startup during its “mobilization” process.

Bank of England governor says no rift with government as Revolut license delay draws scrutiny

The fintech giant was granted a banking license with restrictions in July 2024 from the U.K.’s PRA, bringing an end to a years-long application process that began back in 2021.

This key victory moved Revolut into what’s known as the “mobilization” phase of a company’s journey toward becoming a full-fledged bank.

During this period, firms are limited to holding only £50,000 of total customer deposits — well below the hundreds of billions of pounds customers deposit with major high street lenders such as Barclays, HSBC and Santander.

Revolut customers in the U.K. are also still served by the company’s e-money unit, instead of its banking entity. This means they are not directly insured by the Financial Services Compensation Scheme, which protects customers up to £85,000 if a firm fails.

Delays to Revolut have been a point of contention for the government, which has come under fire from the U.K. tech industry for not doing enough to ensure the country can compete effectively with the U.S. and other key hubs.

Bailey stressed that there was “no trade off between financial stability and growth in the economy.” However, he suggested that he was open to rule changes to enable the fintech sector to flourish.

“We are very open to making changes where they’re appropriate,” he said.



Source

Finland’s IQM to become one of Europe’s first listed quantum companies at .8 billion valuation
World

Finland’s IQM to become one of Europe’s first listed quantum companies at $1.8 billion valuation

European startup IQM is aiming to build powerful quantum computers to rival the likes of Google and IBM. IQM Finland-based quantum computing startup IQM announced plans Monday to become one of Europe’s first publicly listed companies in the sector. IQM will merge with special purpose acquisition company (SPAC), Real Asset Acquisition Corp. (RAAQ) as part […]

Read More
Treasury yields hold steady as investors weigh new Trump tariffs
World

Treasury yields hold steady as investors weigh new Trump tariffs

U.S. Treasury yields were little changed to start the week as investors weighed President Donald Trump’s latest tariffs, after the Supreme Court struck down much of the duties on Friday. At 6:03 a.m. ET, the 10-year Treasury yield was down 1 basis point at 4.075%. The 30-year Treasury bond yield was also less than 1 basis point lower […]

Read More
Novo Nordisk sinks 10% after weight loss drug fails to match Eli Lilly’s in trial
World

Novo Nordisk sinks 10% after weight loss drug fails to match Eli Lilly’s in trial

Novo Nordisk stock fell over 10% Monday after it said its next-generation weight loss drug didn’t meet its primary target. The drug, CagriSema, didn’t achieve its primary endpoint of demonstrating non-inferiority on weight loss when compared to Eli Lilly‘s rival drug tirzepatide after 84 weeks, Novo said in a statement Monday morning. Eli Lilly‘s stock […]

Read More